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Pancreatic exocrine insuﬃciency is a frequently observed phenomenon in type 1 and type 2 diabetes mellitus. Alterations of
exocrine pancreatic morphology can also be found frequently in diabetic patients. Several hypotheses try to explain these ﬁndings,
including lack of insulin as a trophic factor for exocrine tissue, changes in secretion and/or action of other islet hormones, and
autoimmunity against common endocrine and exocrine antigens. Another explanation might be that diabetes mellitus could also
be a consequence of underlying pancreatic diseases (e.g., chronic pancreatitis). Another pathophysiological concept proposes the
functional and morphological alterations as a consequence of diabetic neuropathy. This paper discusses the currently available
studies on this subject and tries to provide an overview of the current concepts of exocrine pancreatic insuﬃciency in diabetes
mellitus.
1.Introduction
Decades ago research groups interested in the pancreas
demonstrated that pancreatic exocrine insuﬃciency (PEI)
is present in a considerable percentage of patients with
diabetes mellitus. These early studies were performed by
direct pancreatic function tests (e.g., secretin-pancreozymin
test). PEI was demonstrated not only in about 50% of
patients with insulin-dependent diabetes (IDDM) but also
in30–50%ofnon-insulin-dependentdiabetes(NIDDM)[1–
6]. Apart from these functional studies it was also observed
that pancreas morphology is altered in many patients with
diabetes mellitus. In IDDM the weight of pancreata was
reduced as compared to healthy controls [7, 8] and there
werehistologicalaspectsofpancreaticatrophy[9].Beforethe
introduction of imaging techniques such as ultrasound, CT,
and MRI, morphological studies of the pancreas in vivo were
diﬃcult. Therefore the collection of data was limited to very
small numbers of patients.
While in most of the discussions and comments the
ﬁnding of altered pancreatic function and morphology was
interpreted as a complication of diabetes mellitus, some
scientists suggested that a high percentage of (previously not
diagnosed) pancreatic diabetes might be a better explanation
[2].However,earlystudiesonpancreaticfunctionindiabetes
were also limited to a rather small number of patients. This
wasduetotheinvasivenatureofthesetestproceduresinclud-
ing tube application into the duodenum and continuous
aspiration of duodenal secretion for several hours.
In the last two decades of the 20th century indirect
pancreatic function test became available. Especially the
measurement of fecal elastase 1 concentrations (FECs) that
can easily be performed in any setting proved rather good
sensitivity and speciﬁcity [10–14]. Using these new indirect
tests, the prevalence of PEI in diabetes mellitus could be
demonstrated to be as high as in the earlier studies: nearly
every second IDDM patient and one out of three NIDDM
patient shows PEI [15–19]. The introduction of ultrasound,
CT, and MRI did facilitate the investigation of pancreas
morphology in vivo resulting in new research activity in the
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The features of modern diagnostic techniques of pan-
creatic function and morphology allowed the investigation
of large patient cohorts. Therefore the reasons for PEI and
morphological changes in diabetes can now be interpreted
on a more solid data base.
In the present paper the relevant literature in this
context is reviewed and discussed. If the thesis of a relevant
percentage of pancreatic diabetes cases proves true, this
will have major impact on our diagnostic and therapeutic
strategies.
2.MaterialandMethods
A Medline-search was performed (March 14th, 2011) using
thefollowingsearchterms:(a)diabetesmellitusandexocrine
pancreatic insuﬃciency (PEI); (b) diabetes mellitus and
elastase 1; (c) diabetes mellitus and pancreatitis; (d) diabetes
mellitus and exocrine pancreatic function; (e) pancreas
morphology and diabetes.
The search terms revealed the following number of
quotations: (a) diabetes mellitus and exocrine pancreatic
insuﬃciency (PEI): 279; (b) diabetes mellitus and elastase 1:
109; (c) diabetes mellitus and pancreatitis: 2321; (d) diabetes
mellitusandexocrinepancreaticfunction,1060;(e)pancreas
morphology and diabetes: 9902.
Most of the papers addressed problems that are not
directly related to the interest of the present review, for
example diabetes and pancreatic cancer or pancreas/islet
transplantation in diabetes mellitus. These were not further
evaluated. The remaining articles were checked for the
prevalence of PEI in diabetes mellitus, the prevalence of
pancreatic diabetes (type 3c), morphological changes of the
pancreas in diabetes mellitus, and the diﬀerent hypotheses
discussed in the context.
3. Results andDiscussion
3.1. Pancreatic Exocrine Function in Diabetes Mellitus. Before
the introduction of indirect function tests several studies
have been performed using direct methods. Table 1 shows
the results reported in these. On average, PEI was reported
in 52.4% (18–100%) of patients with diabetes mellitus. PEI
was reported more often in patients with IDDM. However,
in some of the studies it was observed equally often in
NIDDM. In Table 2 the results of studies using indirect
function tests are shown. On average 51% (26–74%) of
patients with IDDM and 32% (28–36%) of patients with
NIDDM showed abnormal exocrine function. While fecal
elastase 1 concentrations (FECs) are considered a diagnostic
tool for pancreatic function of unknown direct relevance for
the clinical situation in terms of maldigestion and associated
symptoms, it has also been shown in the meantime that
in fact steatorrhea can be detected in 60% of patients
with diabetes mellitus and reduced FEC [26]. In another
previous study it was demonstrated that in 74% of patients
classiﬁed as type 1 diabetes mellitus steatorrhea was present
andsteatorrheacorrelatedinverselywithFECconcentrations
[27]. While one follow-up study in only 20 patients claimed
that a progression of PEI is rare in diabetes mellitus [28],
it must be concluded from the information presently avail-
able that in patients with diabetes mellitus PEI is not only
very frequent in terms of pathological function tests but
also in terms of fat maldigestion. This ﬁnding might explain
abdominal symptoms in patients with diabetes mellitus.
Qualitative malnutrition (fat soluble vitamins) must also
be considered. Most interestingly, the incretin action might
be altered in patients with steatorrhea [29] as the secretion
of incretins depends on the presence of digestive products
inside the digestive tract [30].
3.2. Pancreatic Exocrine Morphology in Diabetes Mellitus.
Autopsy studies and studies on pancreas histology showed
marked changes in the exocrine gland in patients with
diabetes mellitus as compared to nondiabetic controls.
Blumenthal reported signs of chronic inﬂammatory changes
of the exocrine pancreas in 11.2% of patients with diabetes
mellitus as compared to 5.3% in nondiabetic patients [31].
In another autopsy study Olsen reported the percentage of
exocrine pancreatic atrophy in diabetic patients to be 19%
compared to 7% in controls [32]. In patients with long-
lasting type 1 diabetes mellitus a reduced weight of the gland
was reported [7, 8]. It was also observed that in IDDM
patients there is histological evidence of exocrine pancreas
atrophy [7, 9]. Even within only 24 hours after the diagnosis
of type 1 diabetes mellitus, severe atrophy of exocrine tissue
around beta cells without remaining insulin activity could
be found while around beta cells with remaining insulin
content no acinar atrophy could be observed [33]. Rahier
et al. showed a clear reduction of weight in the glucagon-
rich lobe, but no atrophy in the pancreatic-polypeptide-rich
lobe despite the lack of beta cells (and therefore the lack of
insulin) [34]. In clinical medicine changes of pancreatic duct
morphology in patients with diabetes mellitus similar to the
changes observed in chronic pancreatitis were observed at
ERCP procedures [35, 36].
With the introduction of the abdominal ultrasound as
a diagnostic tool, the investigation of the pancreas became
easier. There are several studies reporting a reduced size of
the pancreas in patients with diabetes mellitus. Compared to
sex- and age-matched controls the pancreata of children and
adolescents with type 1 diabetes mellitus appeared clearly
smaller [37]. Similar ultrasound changes were demonstrated
in adults with type 1 and type 2 diabetes mellitus [38]a n db y
u s eo fC Ta n dM R It e c h n o l o g y[ 39, 40].
3.3. HypothesisExplainingPancreaticDamageinPatientswith
Diabetes Mellitus
3.3.1. Insulin as a Trophic Factor for Exocrine Tissue. In the
second half of the last century it was shown that insulin
acts as a trophic factor on acinar tissue [41]. There is a
kind of portal vessel system supplying acinar cells directly
with blood from nearby islets. Acinar cells located closely
to these vessels are bigger and produce more enzymes than
those located more distant [42]. But insulin is not only
a local trophic factor, it also increases the enzyme output
from cultivated islets [43]. In rats with glucose-stimulated
insulin secretion the amount of total amylase and proteinExperimental Diabetes Research 3
Table 1: Results of direct pancreatic function tests in patients with diabetes mellitus.
Author Year Subjects/diabetes type Methods Results
Pollard et al. [1] 1943 13 Amylase and lipase after
pancreozymin-secretin stimulation 62% reduced
Chey et al. [2] 1963 50 diabetic patients; 13 juvenile type Amylase and lipase after
pancreozymin-secretin stimulation
Low amylase output in diabetes:
36%; in juvenile diabetes: 77%
Vacca et al. [3] 1964 55 diabetic patients
(22 insulin treated)
Diastase and bicarbonate after
secretin stimulation; fecal fat
73% abnormal; correlation with
age, no correlation with fecal fat
Frier et al. [4] 1976 20 IDDM, 7 NIDDM, 13 controls Stimulation with iv secretin and
CCK-PZ
PEI: 80% IDDM; correlation with
diabetes duration
Harano et al.
[20] 1978 53 NIDDM, 4 IDDM, 18 controls Secretin-pancreozymin test
Diabetes: 69% deﬁcient enzyme
output; correlation with diabetes
control
Lankisch et al.
[5] 1982 53 IDDM Secretin-pancreozymin test Diabetes: 43% impaired function
Bretzke et al.
[21] 1984 60 insulin-treated type 2 diabetic
patients Secretin-pancreozymin test Diabetes: 27% “mild PEI”
El Newihi et al.
[22] 1988 10 type 2 diabetic patients with
diarrhea and neuropathy Secretin and CCK test Enzyme and bicarbonate reduction
in all subjects
Table 2: Results of indirect pancreatic function tests in patients with diabetes mellitus.
Author Year Subjects/diabetes type Methods Results
Hardt and Kloer [23] 1998 128
type 1+2
Fecal chymotrypsin
Fecal elastase 1
45% <6U / I
46% <200μg/g
Hardt et al. [15] 2000 39 type 1
77 type 2 Fecal elastase 1 74% <200μg/g
36% <200μg/g
Icks et al. [18] 2001 112 type 1 Fecal elastase 1 54.5% <200μg/g
Rathmann et al. [17] 2001 544 type 2 Fecal elastase 1 30.3% <200 μg/g
Hardt et al. [16] 2003 323 type 1
697 type 2 Fecal elastase 1 51% <200μg/g
35% < 200μg/g
Nunes et al. [24] 2003 42 type 1+2 Fecal elastase 1 36% <200μg/g
Yilmaztepe et al. [25] 2005 32 type 2 Fecal elastase 1 28% <200μg/g
Cavalot et al. [19] 2004 66 type 1 Fecal elastase 1 26% <200μg/g
content is higher than that in diabetic rats [42]. From these
observations in animal models and cell culture models it
has been concluded that pancreatic atrophy as observed in
some patients with diabetes mellitus might result from a
lack of local trophic insulin eﬀects. This hypothesis was
supported by the fact that patients without any beta cell
function display more obvious morphological changes than
those with some residual insulin secretion [44]. Therefore
it appears to be possible that local insulin depletion might
explain morphological changes and exocrine dysfunction in
some of the patients with diabetes mellitus. This concept was
further supported by the observations of Cavalot et al. who
reported a correlation between residual beta cell function
and FEC [19]. However, if the local presence of insulin had
s u c ham a j o rt r o p h i ce ﬀect, it is diﬃcult to understand why
about 50% of patients with type 1 diabetes do not show any
relevant changes of the exocrine pancreas. Furthermore this
hypothesisdoesnotexplaintheﬁndingsinpatientswithtype
2 diabetes mellitus since there is no local lack of insulin to be
expected, at least in the early stages of the disease.
Inconclusiontheconceptofalackoflocaltrophicinsulin
action might explain some of the phenomena observed;
however it cannot explain the whole phenomenon.
3.3.2. Changes in Secretion/Action of Other Islet Hormones.
Apart from the changes in insulin secretion or action,
other islet cell hormones are also known to act diﬀerently
in patients with diabetes mellitus as compared to healthy
controls. Some of them play an important role in the
regulationofdigestiveandmetabolicfunctionsandtherefore
they might also lead to a dysregulation of the exocrine
pancreatic function [45]. As a consequence atrophy might
result. A persisting elevation of glucagon levels as observed
in some diabetic patients has been suggested to contribute
to exocrine damage and dysfunction [46, 47]. Somatostatin
is a relevant regulator of exocrine function [48], and ele-
vated levels, as described in streptozotocin-induced diabetes
mellitus, have been shown to reduce exocrine pancreatic
function [49]. While changes in glucagon and somatostatin
secretion might also contribute to exocrine damage in some4 Experimental Diabetes Research
of the patients with diabetes mellitus, they also do not fully
explain the phenomena described in detail above. Some of
thestudieswereonlyperformedinanimalmodels.and,more
importantly, the patterns of secretory changes diﬀer in type
1 and type 2 diabetes mellitus.
3.3.3. Autoimmunity. Autoimmune pancreatitis has gained
more attention previously. In the diﬀerent types of the
disease that have been described an involvement of both,
exocrine and endocrine tissue, is very frequent. Diabetes
mellitus associated with autoimmune pancreatitis can be
treated by steroids, and it can even be cured if the
autoimmune attack can be stopped [50, 51]. Apart from
these cases exocrine antigens might also play a role in the
induction of autoimmunity against beta cells in the absence
of classical autoimmune diabetes. Some decades ago it has
been demonstrated mainly from Japanese scientists that in
some subtypes of diabetes mellitus antibodies are present
which are directed against exocrine antigens. Kobayashi et
al. described antibodies against pancreatic cytokeratin in
39% of recent onset patients classiﬁed as type 1 diabetes
mellitus and in 20% of their relatives. In type 2 diabetes
mellitus patients only 0.9% had relevant antibody titers.
The authors suggested that the ultrastructure of exocrine
tissue might be involved in the pathogenesis of type 1
diabetes mellitus [52]. Another antibody against exocrine
tissue (BSDL) was found in 73.5% of patients at diagnosis of
type 1 diabetes mellitus [53]. Imagawa et al. even suggested
the introduction of a new diabetes type: patients with
rapid loss of insulin secretion but without the presence of
islet- or insulin-associated autoimmunity. On histological
samples their patients displayed a marked inﬂammation in
the exocrine tissue with elevated levels of pancreatic enzymes
[54]. In another study antibodies against lactoferrin or
carbonic anhydrase (both directed against exocrine targets)
were present in 77% of patients classiﬁed as type 1 diabetes
mellitus [55].
While the quantitative input of autoimmune pancreatitis
associated with diabetes mellitus surely is rather small, the
possible relevance of exocrine antigens in the pathogenesis
of autoimmune diabetes deserves further attention.
3.3.4. Diabetes Mellitus as a Consequence of Underlying Pan-
creatic Diseases. While PEI might be induced by diabetes
mellitus, it could as well be the other way around as it
has been proposed as early as 1963 by Chey et al. [2].
Diﬀerent pancreatic diseases are known to induce diabetes
mellitus, including diﬀerent types of pancreatitis, pancreatic
carcinoma, cystic ﬁbrosis, and hemochromatosis. However,
these diseases are believed to contribute to the burden of
diabetes mellitus in only about 1% of all cases [56, 57]. The
possibility that the prevalence of pancreatic diabetes might
well be much higher than 1% has been discussed in detail
elsewhere [58] and will not be issue of the present paper.
Additionally to those hypotheses explaining pancre-
atic damage in patients with diabetes mellitus, pancreatic
exocrine insuﬃciency might also be interpreted as a compli-
cation of diabetic neuropathy.
3.4. Pancreatic Exocrine Insuﬃciency as a Complication of
Diabetic Neuropathy. Diabetic neuropathy (DN) is a com-
plication of diabetes mellitus that might occur in the time
course of the disease. While the prevalence of DN is about
4–7.5% at the time of diagnosis, it is observed in 15–50%
of the patients after 20–25 years of diabetes mellitus [59].
Autonomicneuropathycanaﬀectnotonlythecardiovascular
system, but also diﬀerent functions of the digestive tract.
Gastrointestinal motor disorders, for example, gastroparesis,
diabetic diarrhea, diabetic obstipation, and fecal inconti-
nence as a complication of diabetes mellitus have been
described in detail [60]. It seems obvious that some of
the gastrointestinal symptoms that occur in patients with
diabetes mellitus are caused by DN. On the other hand,
diabetic diarrhea and bloating might arise from the exocrine
insuﬃciency that is probably even more common than DN
in patients with diabetes mellitus. Since the regulation of
enzyme synthesis and secretion does not only depend on
gastrointestinalhormonesproducedsomewhereelsebutalso
on local neurons and their signals, exocrine insuﬃciency
itself could be caused by DN. This possibility has been taken
into consideration in several studies dating back to the last
century. However, one main argument against the assump-
tion that DN might cause PEI was the lack of correlation
between the duration of diabetes mellitus and the ﬁnding
of exocrine insuﬃciency [2, 3]. However, more recently two
studies [19, 61] demonstrated a signiﬁcant increase of PEI
in the time course of diabetes mellitus. Cavalot had shown
earlier that fecal elastase 1 levels are correlated with the
remainingC-peptidelevelsin37patientswithtype1diabetes
mellitus suggesting that the remaining insulin presence
mightbeofrelevanceforexocrinepancreaticfunction.While
thisexplanationwasincontrasttomostotherpublicationsat
that time, the ﬁnding could also be interpreted diﬀerently:
C-peptide levels are known to decrease by time in type 1
diabetes mellitus while the probability of DN does increase.
In fact, there was also a weak inverse correlation between
diabetes duration and PEI despite the small number of
individuals included in the study [26]. A more recent study
by Ewald et al. involved data from 307 patients with diﬀerent
types of diabetes. Diabetes duration was inversely correlated
with fecal elastase 1 concentrations (P = 0.004), and there
was also a correlation between C-peptide levels and FEC
(P<0.001) [61]. The fact that earlier studies missed to
show a correlation between disease duration and exocrine
pancreatic function might be explained by smaller patient
numbers that had been included into these studies.
Mechanisms linking exocrine pancreatic insuﬃciency
might be the impairment of enteropancreatic reﬂexes or
changes in gastrointestinal peptides. Enteropancreatic reﬂex-
es for example are known to play an important role in pan-
creatic responses, and according to older data as much as
50% of the exocrine pancreatic response to a meal may be
mediated by enteropancreatic reﬂexes [22]. Interruption of
the enteropancreatic reﬂexes by an autonomic neuropathy
mightthereforeseverelyimpairexocrinepancreaticfunction.
Yetdataonthistopicisscarceandfurtherresearchisstrongly
encouraged.Experimental Diabetes Research 5
4. Conclusion
In the light of the literature reviewed for this paper there is
clear evidence that both pancreas morphology and exocrine
pancreatic function are very frequently and severely altered
in patients with diﬀerent types of diabetes mellitus. Several
hypotheses have been discussed to explain these ﬁndings.
A high prevalence of diabetes caused by pancreatic dis-
eases (including autoimmune pancreatitis) appears unlikely
because pancreatic diseases themselves have a low prevalence
according to the clinical literature. Lack of local trophic
insulin action causing acinar atrophy does not explain the
fact that most patients with type 1 diabetes mellitus have no
signs of exocrine changes. If local insulin deﬁciency was the
mainissue,anexocrineinvolvementshouldbeexpectedinall
patients with type 1 diabetes mellitus. The assumption that
changes in hormonal secretion patterns in diabetic patients
might explain exocrine pathology is also very unlikely for
diﬀerent reasons. However, as the prevalence of pancreatic
exocrine insuﬃciency increases with decreasing C-peptide
levels and over time, exocrine involvement might well be
interpreted as a complication of diabetes mellitus that could
be caused by diabetic neuropathy. At present, only very few
studies directly interested in possible correlations between
diabetic neuropathy and exocrine pancreatic dysfunction are
available. There is one study by Vesterhus et al. describing
a predominantly demyelinating neuropathy in a special
diabetes type caused by a mutation in the CEL gene that
includes pancreatic insuﬃciency. However, the presence of
neuropathywasmainlyattributedtothelowvitaminDlevels
caused by PEI [62]. The second observation was made in a
single case where neuropathy was also interpreted as a conse-
quence of PEI in diabetes mellitus [63]. Larger studies on the
association of diabetic neuropathy and exocrine pancreatic
insuﬃciency should therefore be strongly encouraged.
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